Nanobiotix S.A. Logo

Nanobiotix S.A.

A late-stage biotech developing physics-based nanotherapeutics to enhance radiotherapy.

NBTX | US

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
United States of America
Address:
60 RUE DE WATTIGNIES, 75012 PARIS

Description

Nanobiotix S.A. is a late-stage clinical biotechnology company that pioneers the development of physics-based nanotherapeutics. The company's lead candidate, NBTXR3, is a potential first-in-class radioenhancer designed to be injected directly into a tumor. It works by amplifying the dose of radiotherapy absorbed by cancer cells without increasing the dose in surrounding healthy tissues. This localized destruction also aims to prime an immune response to attack metastatic tumors. Nanobiotix is engaged in a global licensing agreement with Janssen Pharmaceutica NV, a Johnson & Johnson company, for the co-development and commercialization of NBTXR3. The initial development focus is on solid tumors, particularly in head, neck, and lung cancers, for patient populations with limited treatment options.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2024-12-15
English
4.2 MB
2024-10-30
German
1.8 MB
2024-08-14
French
0.5 MB
2024-05-22
English
2.1 MB
2024-03-10
English
3.5 MB
2024-01-15
German
1.2 MB
2023-11-20
English
5.1 MB

Full Filing History Restricted

Access to specific historical documents or filtered results is limited in the Web UI. Request access to the complete dataset.

Automate Your Workflow. Get a real-time feed of all Nanobiotix S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Nanobiotix S.A.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Nanobiotix S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Biopharmaceutical firm developing cannabinoid-based medicines for inflammatory conditions.
United Kingdom
ANAN
Designs, develops, and manufactures molecular diagnostic solutions and instruments.
Türkiye
ANGEN
ANAVEX LIFE SCIENCES CORP. Logo
Clinical-stage biopharmaceutical company developing therapeutics for CNS disorders.
United States of America
AVXL
Anbio Biotechnology Logo
Develops and provides in-vitro diagnostic (IVD) solutions and instruments.
United States of America
NNNN
Anebulo Pharmaceuticals, Inc. Logo
Clinical-stage biotech developing therapies for acute cannabinoid intoxication.
United States of America
ANEB
AnGes, Inc. Logo
Biopharmaceutical firm developing gene-based and nucleotide-based medicines.
Japan
4563
Anika Therapeutics, Inc. Logo
A global joint preservation company developing solutions for orthopedic care.
United States of America
ANIK
ANIMALCARE GROUP PLC Logo
Develops and commercializes veterinary pharmaceutical products and services globally.
United Kingdom
ANCR
ANI PHARMACEUTICALS INC Logo
Develops, manufactures, and markets branded, generic, and OTC pharmaceutical products.
United States of America
ANIP
Annexin Pharmaceuticals AB Logo
Clinical-stage biotech developing a cell-protecting biologic for RVO and oncology.
Sweden
ANNX

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.